DURHAM, NC--(Marketwire - February 27, 2008) - Serenex, Inc., a leader in the discovery and development of small molecule Heat Shock Protein 90 (Hsp90) inhibitors, today announced the signing of a Clinical Trial Agreement (CTA) with the Center for Cancer Research (CCR) at the National Cancer Institute (NCI). Under this CTA, Dr. Guiseppe Giaccone, Chief of the Medical Oncology Branch at NCI and his colleague, Dr. Martin Gutierrez, will conduct a phase 1 clinical trial with Serenex’s novel, oral, small molecule Hsp90 inhibitor, SNX-5422.
